8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Earliest Event Reported: October 24, 2005

 


 

MONOGRAM BIOSCIENCES, INC.

(Exact Name of Registrant as Specified in Charter)

 


 

Delaware   000-30369   94-3234479

(State or Other Jurisdiction

of Incorporation)

  (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

345 Oyster Point Blvd., South San Francisco, California, 94080

(Address of Principal Executive Offices, including zip code)

 

(650) 635-1100

(Registrant’s Telephone Number, including area code)

 

 

(Former Name or Former Address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 2.02. Results of Operations and Financial Condition.

 

On October 24, 2005, Monogram Biosciences, Inc. issued a press release announcing financial results for the quarter ended September 30, 2005. A copy of this press release, entitled “Monogram Announces Third Quarter 2005 Financial Results,” is furnished herewith as Exhibit 99.1.

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit

Number


 

Description


99.1   Press Release, entitled “Monogram Announces Third Quarter 2005 Financial Results” dated October 24, 2005.


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

Monogram Biosciences, Inc.

(Registrant)

Date: October 24, 2005

 

By:

 

/s/ Kathy L. Hibbs


       

Kathy L. Hibbs

       

Vice President, General Counsel


INDEX TO EXHIBITS

 

Exhibit
Number


 

Description


99.1   Press Release, entitled “Monogram Announces Third Quarter 2005 Financial Results” dated October 24, 2005.